Adamas Pharmaceuticals was founded in 2002 and is headquartered in Emeryville, US

Chief Executive Officer & Chairman

Chief Financial Officer

Director

Adamas Pharmaceuticals has an office in Emeryville

Emeryville, US (HQ)

750 1900 Powell St

Adamas Pharmaceuticals's revenue was reported to be $0 in Q1, 2017

USD

## Net income (Q1, 2017) | (16 m) |

## EBIT (Q1, 2017) | (16.2 m) |

## Market capitalization (17-Aug-2017) | 313.9 m |

## Cash (31-Mar-2017) | 20.9 m |

Adamas Pharmaceuticals's current market capitalization is $313.9 m.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 55.8 m | 1.9 m | 572 k |

## Revenue growth, % | (97%) | (70%) | |

## R&D expense | 21.9 m | 35.9 m | 31.2 m |

## General and administrative expense | 15.5 m | 23.5 m | |

## Operating expense total | 37.3 m | 59.4 m | 61.6 m |

## EBIT | 18.5 m | (57.4 m) | (61 m) |

## EBIT margin, % | 33% | (2998%) | (10662%) |

## Interest income | (917 k) | 363 k | 811 k |

## Pre tax profit | 17.6 m | (57.1 m) | (60.2 m) |

## Income tax expense | (7.4 m) | (5.3 m) | (115 k) |

## Net Income | 10.2 m | (51.8 m) | (60.1 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 25.2 m | 215 k | 226 k | 398 k | 768 k | 175 k | 222 k | 138 k | |

## R&D expense | 5.2 m | 5.4 m | 7.5 m | 8.7 m | 10 m | 7.5 m | 9.2 m | 7.4 m | 7.1 m |

## General and administrative expense | 3.3 m | 4.4 m | 4.9 m | 5.8 m | 5.8 m | ||||

## Operating expense total | 8.4 m | 9.8 m | 12.5 m | 14.6 m | 15.8 m | 7.5 m | 9.2 m | 7.4 m | 7.1 m |

## EBIT | 16.7 m | (9.6 m) | (12.2 m) | (14.2 m) | (15 m) | (14 m) | (17.1 m) | (14.6 m) | (16.2 m) |

## EBIT margin, % | 66% | (4442%) | (5410%) | (3556%) | (1952%) | (7993%) | (7685%) | (10611%) | |

## Interest income | 78 k | 102 k | 85 k | 160 k | 184 k | 249 k | 204 k | ||

## Pre tax profit | 16.6 m | (9.6 m) | (12.1 m) | (14.1 m) | (14.9 m) | (13.8 m) | (16.9 m) | (14.4 m) | |

## Income tax expense | (178 k) | (6 k) | (54 k) | (178 k) | (51 k) | 54 k | |||

## Net Income | 16.4 m | (9.6 m) | (12.2 m) | (14.1 m) | (14.9 m) | (13.8 m) | (16.9 m) | (14.4 m) | (16 m) |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 61.4 m | 33.1 m | 23.7 m |

## Accounts Receivable | 524 k | 1.3 m | 794 k |

## Inventories | 645 k | 5.1 m | 2.5 m |

## Current Assets | 123.5 m | 113.2 m | 117 m |

## PP&E | 1.2 m | 2.4 m | 3.2 m |

## Total Assets | 161.2 m | 128.7 m | 142.5 m |

## Accounts Payable | 3.7 m | 3.1 m | 3.6 m |

## Current Liabilities | 12.5 m | 11.8 m | 9.7 m |

## Non-Current Liabilities | 749 k | 547 k | |

## Total Liabilities | 12.6 m | 10.3 m | |

## Additional Paid-in Capital | 157.6 m | 178.5 m | 254.6 m |

## Retained Earnings | (10.3 m) | (62.2 m) | (122.2 m) |

## Total Equity | 147.1 m | 116.2 m | 132.2 m |

## Financial Leverage | 1.1 x | 1.1 x | 1.1 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 144.6 m | 137.5 m | 29.2 m | 37.9 m | 37.1 m | 98.4 m | 109.3 m | 9.8 m | 20.9 m |

## Accounts Receivable | 218 k | 120 k | 485 k | 361 k | 936 k | 461 k | 860 k | 769 k | 1.7 m |

## Current Assets | 145.8 m | 138.9 m | 115.5 m | 126.4 m | 105.5 m | 169.6 m | 163.3 m | 110.4 m | 115.2 m |

## PP&E | 336 k | 443 k | 1.3 m | 2 m | 2.1 m | 2.9 m | 3.4 m | 3.1 m | 3.1 m |

## Total Assets | 146.2 m | 139.4 m | 147.3 m | 147.1 m | 136.8 m | 178.5 m | 168.6 m | 157.2 m | 128.5 m |

## Accounts Payable | 3.3 m | 3 m | 3.8 m | 3.9 m | 2.9 m | 3.5 m | 4.7 m | 6 m | 3 m |

## Current Liabilities | 6 m | 6.7 m | 8.1 m | 10 m | 11 m | 10.7 m | 12.8 m | 12.6 m | 8.3 m |

## Non-Current Liabilities | 8 k | 1.7 m | 1.9 m | 1.8 m | 699 k | 649 k | 600 k | 492 k | |

## Additional Paid-in Capital | 150.7 m | 152.8 m | 160.1 m | 171.7 m | 175.4 m | 243 m | 248 m | 251.4 m | 258.1 m |

## Retained Earnings | (10.5 m) | (20.1 m) | (22.6 m) | (36.6 m) | (51.5 m) | (76 m) | (92.9 m) | (107.2 m) | (138.2 m) |

## Total Equity | 140.2 m | 132.7 m | 137.6 m | 135.1 m | 124 m | 167.1 m | 155.2 m | 144.1 m | 119.7 m |

## Financial Leverage | 1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | 10.2 m | (51.8 m) | (60.1 m) |

## Depreciation and Amortization | 155 k | 435 k | 808 k |

## Accounts Receivable | (395 k) | (760 k) | 490 k |

## Inventories | (97.8 m) | (153.7 m) | 2.1 m |

## Accounts Payable | 1.5 m | (788 k) | 502 k |

## Cash From Operating Activities | (24.2 m) | (28.3 m) | (48.1 m) |

## Purchases of PP&E | (1.3 m) | (1.4 m) | (1.6 m) |

## Cash From Investing Activities | (97.4 m) | 8.1 m | (26.7 m) |

## Cash From Financing Activities | 47 m | 10.8 m | 65.4 m |

## Interest Paid | 279 k | 279 k | |

## Income Taxes Paid | 341 k | 4.7 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 16.4 m | (9.6 m) | (12.2 m) | (14.1 m) | (14.9 m) | (13.8 m) | (16.9 m) | (14.4 m) | (16 m) |

## Accounts Receivable | 218 k | 120 k | 485 k | 361 k | 936 k | 461 k | 860 k | 769 k | 1.7 m |

## Accounts Payable | 3.3 m | 3 m | 3.8 m | 3.9 m | 2.9 m | 3.5 m | 4.7 m | 6 m | 3 m |

Y, 2017 | |
---|---|

## Financial Leverage | 1.1 x |